Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive TCR Changes Name to Adaptive Biotechnologies

Premium

Adaptive TCR has changed its name to Adaptive Biotechnologies, the company said this week.

The Seattle-based firm provides next-generation sequencing assays under the brand name ImmunoSeq to analyze the adaptive immune system.

Last summer, it raised $5.8 million in a Series B round to grow its services and invest in clinical applications (CSN 6/15/2011).

According to the company's CEO, Chad Robins, the name change better reflects "the full nature and potential" of its products and services, which include T-cell and B-cell receptor sequencing as well as the development of clinical applications for the diagnosis and prognosis of cancer.

Clinical applications include monitoring minimal residual disease in blood-based cancers, more accurate measurements for immune reconstitution after transplantation, and direct measurement of tumor-infiltrating lymphocytes as a prognostic indicator of ovarian cancer. The company is also developing threshold tests to stratify patients into clinical trials, and to predict their response to therapeutics and vaccines.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.